Anthony Zampino
Neurology · Willoughby, OHNPI 1427518505
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,396, more than ten times the $17 reported in 2023.
Across 105 payments — averaging $23.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$575
- UCB, Inc.$495
- AbbVie$318
- Argenx US, Inc.$216
- Sanofi$182
- Pfizer$107
- plus $553 from 13 others
Across 3 payments — averaging $21,380 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$64K
What the payments were for
- Food & beverage$2,445100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 26 | $575 |
| UCB, Inc. | 17 | $495 |
| AbbVie | 16 | $318 |
| Argenx US, Inc. | 10 | $216 |
| Sanofi | 3 | $182 |
| Pfizer | 5 | $107 |
| Jazz Pharmaceuticals Inc. | 5 | $99 |
| Biogen | 5 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $82 |
| Genentech USA, Inc. | 3 | $65 |
| Vanda Pharmaceuticals Inc. | 2 | $52 |
| Springworks Therapeutics, Inc. | 2 | $37 |
| Averitas Pharma Inc. | 1 | $30 |
| Lundbeck LLC | 1 | $22 |
| Amylyx Pharmaceuticals, Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Grifols USA, LLC | 1 | $16 |
| Tanabe Pharma America, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
How this compares
$2,445 in reported general payments places this provider in the 60th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 11 | $68,470 |
| Mexiletine Hcl | 11 | $484 |
| Megestrol Acetate | 11 | $439 |
| Gabapentin | 47 | $438 |
| Prednisone | 20 | $119 |
| Zonisamide | 11 | $98 |
Paid to pharmacies, not to this prescriber.
Other neurology in Willoughby
- Morris LevinsohnWilloughby$192K
- Aram ZabetiCincinnati$1.6M
- Kenneth MankowskiColumbus$1.4M
- Aaron BosterColumbus$1.2M
- Martin TaylorNew Albany$821K
- Jacqueline NicholasColumbus$743K
- Lawrence ElmerToledo$687K
- Kenneth PugarCenterville$582K
- Brendan BauerSheffield Village$548K
- Geoffrey EubankColumbus$508K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.